Division of Infectious Diseases and HIV Medicine, Case School of Medicine and the University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA,
Curr Infect Dis Rep. 2011 Feb;13(1):21-7. doi: 10.1007/s11908-010-0155-7.
Clostridium difficile infection (CDI) is a leading cause of nosocomial infections and the most important cause of health care-associated diarrhea worldwide. Standard treatment of CDI consists of modifying underlying antibiotic exposure, aggressive supportive measures, and therapy with specific antibiotics, most commonly metronidazole or vancomycin. This general approach to CDI has remained largely unchanged for decades. In an effort to improve outcomes and reduce recurrences of CDI, interest has been renewed in the development of nonantibiotic and adjunct approaches to therapy. In this review, we highlight some of these recent, resurrected, and novel nonantibiotic treatments.
艰难梭菌感染（CDI）是医院获得性感染的主要原因，也是全球最重要的与医疗保健相关的腹泻病因。CDI 的标准治疗包括调整潜在的抗生素暴露、积极的支持措施以及使用特定抗生素进行治疗，最常用的是甲硝唑或万古霉素。几十年来，这种治疗 CDI 的一般方法基本保持不变。为了改善 CDI 的治疗效果并降低其复发率，人们重新关注非抗生素和辅助治疗方法的开发。在这篇综述中，我们重点介绍了一些最近、重新出现和新型的非抗生素治疗方法。
